A Study of LY2157299 in Participants With Hepatocellular Carcinoma

The purpose of this study is to estimate the median time to progression in participants with hepatocellular carcinoma (HCC) when treated with LY2157299 as monotherapy and in combination with sorafenib or ramucirumab.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Liver Cancer
What the trial is testing?
Galunisertib, Sorafenib, Ramucirumab
Could I receive a Placebo?
No
Enrollment Goal
204
Trial Dates
Mar 30, 2011 - Dec 24, 2019
How long will I be in the trial?
Trial Phase
II

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.